Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients

pharmaceutical-technologyFebruary 26, 2019

Tag: AstraZeneca , CAD , Diabetes , Brilinta

PharmaSources Customer Service